Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Inventors

Remarchuk, Travis • Sudhakar, Anantha

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11834438-B2

Patent

Publication Date

2023-12-05

Expiration Date


Abstract

The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.

Core Innovation

The patent describes a process for preparing a specified pyrimidinyl-4-aminopyrazole compound of formula I, or a salt thereof, from compounds of formula II and formula III in the presence of a Lewis acid. The described transformation is regioselective displacement of L while retaining X; the supplied content also identifies zinc chloride among the Lewis acids and the compound as an LRRK2 inhibitor.

The background section is not included in the partial content, so the problem addressed in that section is not explicitly described. The supplied description also refers to further transformations and purification of the compound, but procedural details are omitted here. It does not provide enough background text to identify any broader problem beyond the disclosed preparation of the specified compound.

Claims Coverage

The provided claim set identifies one independent claim, claim 1, covering one principal inventive feature.

Preparation of the specified formula I compound

The claim covers preparation of the specified compound of formula I, or a salt thereof, using compounds of formula II and formula III and a Lewis acid. [procedural detail omitted for safety]

The independent claim concerns preparation of the specified formula I compound using a Lewis acid; the dependent claims further specify purification, selection of zinc chloride, formulation with an excipient, and capsule or tablet dosage forms.

Stated Advantages

Not explicitly described in patent.

Documented Applications

The compound is identified as an LRRK2 inhibitor.

A dependent claim describes processing a composition containing the compound and an excipient into a capsule or tablet.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.